The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography
Abstract
BACKGROUND: Numerous knockout mouse studies have revealed that P-glycoprotein (P-gp) significantly limits drug distribution across the mouse blood-brain barrier (BBB). To determine the importance of P-gp at the human BBB, we developed a state-of-the-art, noninvasive, quantitative imaging technique to measure P-gp activity by use of carbon 11-labeled verapamil as the P-gp substrate and cyclosporine (INN, ciclosporin) as the P-gp inhibitor. METHODS: In brief, 11C-verapamil (approximately 0.2 mCi/kg) was administered to healthy volunteers (n = 12 [6 women and 6 men]) as an intravenous infusion over a period of approximately 1 minute before and after at least a 1-hour infusion of cyclosporine (2.5 mg x kg(-1) x h(-1)). Arterial blood samples and brain positron emission tomography images were obtained at frequent intervals for 45 minutes. Both blood and plasma radioactivity contents were determined in each verapamil sample. The content of verapamil and its metabolites in the 20- and 45-minute plasma samples was determined by a rapid solid-phase extraction method. The brain uptake of 11C-radioactivity (brain area under the curve [AUCbrain ]/blood area under the curve [AUCblood]) was determined in the presence and absence of cyclosporine. RESULTS: The AUCbrain/AUCblood ratio of 11C-radioactivity was increased by 88% +/- 20% (1.02 +/- 0.18 versus 0.55 +/- 0.10, P < .001) in the presence of cyclosporine (mean blood concentration, 2.8 +/- 0.4 micromol/L) without affecting 11C-verapamil metabolism or plasma protein binding. The corresponding increases for the brain white and gray matter were 84% +/- 13% and 84% +/- 18%, respectively. CONCLUSIONS: This is the first time that P-gp activity at the human BBB has been measured. The modest inhibition of human BBB P-gp by cyclosporine has implications for P-gp-based drug interactions at the human BBB. Our method for imaging P-gp activity can be used to identify multidrug-resistant tumors or to determine the contribution of P-gp polymorphism, inhibition, or induction to interindividual variability in drug response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mammalian ABC Transporters in Health and Disease
Borst, P., & Elferink, R. O. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.102301.093055 · Cited by 1,571
Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J., Roden, D. M., & Wilkinson, G. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1269 · Cited by 1,054
Brain blood flow measured with intravenous H2(15)O. II. Implementation and validation.
Raichle, M. E., Martin, W. R. W., Herscovitch, P., Mintun, M. A., & Markham, J. (1983) · PubMed · Cited by 1,015
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
Marzolini, C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.012 · Cited by 895
Loe, D. W., Almquist, K. C., Deeley, R. G., & Cole, S. P. C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.16.9675 · Cited by 560
Litman, T., Brangi, M., Hudson, E., Fetsch, P., Abati, A., Ross, D. D., Miyake, K., Resau, J. H., & Bates, S. E. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.11.2011 · Cited by 538
Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.
Piwnica-Worms, D. R., Chiu, M. L., Budding, M., Kronauge, J. F., Kramer, R. A., & Croop, J. M. (1993) · PubMed · Cited by 512
Increased drug delivery to the brain by P-glycoprotein inhibition
Sadeque, A. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109156 · Cited by 426
Genetic Polymorphisms of the Human MDR1 Drug Transporter
Schwab, M., Eichelbaum, M., & Fromm, M. F. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140233 · Cited by 308
Minoshima, S., Berger, K. L., Lee, K. S., & Mintun, M. A. (1992) · PubMed · Cited by 265
Cited by
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors
Uchida, Y., Ohtsuki, S., Katsukura, Y., Ikeda, C., Suzuki, T., Kamiie, J., & Terasaki, T. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07208.x · Cited by 881
The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses
Deeken, J. F., & Löscher, W. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2854 · Cited by 721
ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Choi, Y., & Yu, A.-M. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282005140214165212 · Cited by 629
ABC Efflux Pump-Based Resistance to Chemotherapy Drugs
Eckford, P. D. W., & Sharom, F. J. (2009) · Chemical Reviews · doi:10.1021/cr9000226 · Cited by 597
On The Rate and Extent of Drug Delivery to the Brain
Hammarlund-Udenaes, M., Fridén, M., Syvänen, S., & Gupta, A. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9502-2 · Cited by 513
Syvänen, S., Lindhe, Ö., Palner, M., Kornum, B. R., Rahman, O., Långström, B., Knudsen, G. M., & Hammarlund-Udenaes, M. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.024745 · Cited by 359
Blood–brain barrier P-glycoprotein function in Alzheimer's disease
van Assema, D. M. E., Lubberink, M., Bauer, M., van der Flier, W. M., Schuit, R. C., Windhorst, A. D., Comans, E. F. I., Hoetjes, N. J., Tolboom, N., Langer, O., et al. (2012) · Brain · doi:10.1093/brain/awr298 · Cited by 318
Chu, X., Bleasby, K., & Evers, R. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.741589 · Cited by 306
Demystifying Brain Penetration in Central Nervous System Drug Discovery: Miniperspective
Di, L., Rong, H., & Feng, B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301297f · Cited by 304
The clinical impact of pharmacogenetics on the treatment of epilepsy
Löscher, W., Klotz, U., Zimprich, F., & Schmidt, D. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01716.x · Cited by 281
Oberoi, R. K., Parrish, K. E., Sio, T. T., Mittapalli, R. K., Elmquist, W. F., & Sarkaria, J. N. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov164 · Cited by 280
Pathways for Small Molecule Delivery to the Central Nervous System across the Blood-Brain Barrier
Mikitsh, J. L., & Chacko, A.-M. (2014) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s13384 · Cited by 271
Deo, A. K., Borson, S., Link, J. M., Domino, K., Eary, J. F., Ke, B., Richards, T. L., Mankoff, D. A., Minoshima, S., O’Sullivan, F., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.130161 · Cited by 193
“Area under the tissue time–activity curve was computed to examine cerebral verapamil distribution, a method previously shown to approximate P-glycoprotein activity at the human BBB (13,15).”
Self-citationBreaking Bad: the Structure and Function of the Blood-Brain Barrier in Epilepsy
Han, H., Mann, A., Ekstein, D., & Eyal, S. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0096-2 · Cited by 83
Minocha, M., Khurana, V., Qin, B., Pal, D., & Mitra, A. K. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.05.028 · Cited by 82
“al wherein, enhanced brain penetration of verapamil; a probe P-gp substrate, was demonstrated using PET imaging upon co-administration of a potent and specific P-gp inhibitor; cyclosporine A (Sasongko et al., 2005).”
Background
Metadata
- Authors
- SASONGKO, L., LINK, J., MUZI, M., MANKOFF, D., YANG, X., COLLIER, A., SHONER, S., & UNADKAT, J.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2005-06
- Volume
- 77
- Issue
- 6
- Pages
- 503-514
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W2140293712
- Cited by
- 271
- References
- 34
- FWCI
- 8.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.